Mass production of Thailand’s ChulaCov 19 mRNA vaccine expected early next year

13 Sept 12:57 Key points summarised by AI

Thailand's ChulaCov 19 mRNA vaccine is slated for mass production and technology transfer to a local manufacturer by the first quarter of next year.
Initial Phase 1 human clinical trials showed promising safety, with no serious side effects in the 18-55 age group and mild reactions resolving quickly.
The research center is preparing for Phase 2 trials and developing a second-generation mRNA vaccine to combat future virus mutations.
A local production unit is being equipped to produce up to five million doses of the vaccine monthly, supporting commercial rollout.

Six injured after car smashes into On Nut shopping mall

Yesterday 22:44 Key points summarised by AI

A 67-year-old woman drove her car through the glass frontage of a Bangkok shopping mall, injuring six people, including a six-year-old girl.
The driver claimed she accidentally pressed the accelerator instead of the brake after being startled, causing the vehicle to surge forward.
She apologized to the victims, promising insurance coverage and additional financial aid, while police continue to gather statements before filing charges.